TAVNEOS
Peakavacopan
NDAORALCAPSULE
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
5/8 — Partial
TAVNEOS (avacopan) is complement 5a receptor antagonists [moa]. First approved in 2021.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAVNEOS (avacopan) is an oral complement C5a receptor antagonist approved in October 2021 for treating ANCA-associated vasculitis (AAV), a rare systemic autoimmune disease. It works by blocking the C5a complement pathway, which drives inflammation in blood vessel walls. This is the first oral complement inhibitor in its class, offering a novel non-immunosuppressive approach to a serious rare disease.
$34MPart D
Peak13.1 years to LOEProduct is in peak phase with modest Part D spending (~$34M in 2023) indicating growing but still niche market penetration appropriate for specialty rare disease team structures.
Mechanism of Action
Complement 5a Receptor Antagonists
Pharmacologic Class:
Complement 5a Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Started May 2026
30 enrolled
Granulomatosis With PolyangiitisWegener'sGPA
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Started Nov 2024
160 enrolled
ANCA Associated Vasculitis (AAV)
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
Started Oct 2024
19 enrolled
Vasculitis
A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
Started Jun 2024
13 enrolled
End-Stage Renal Disease (ESRD)
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Started Feb 2024
300 enrolled
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.